O
Oxford BioTherapeutics
Clinical-stage oncology antibody-based cancer therapies developer
About Oxford BioTherapeutics
Oxford BioTherapeutics is a clinical-stage oncology company that develops antibody-based therapies for cancer patients. The company was founded in 2004 by Dr. Christian Rohlff, who serves as the CEO. Dr. Rohlff has over two decades of experience in the international biotechnology industry, having held positions at the US National Cancer Institute and Oxford Glycosciences.
The company's core technology is its proprietary OGAP® target discovery platform. OGAP® is one of the world's largest proteomic databases, containing information on thousands of cancer cell proteins, which allows for the identification of novel oncology targets. This platform has enabled the development of a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies. These therapies include bispecifics, Chimeric Antigen Receptor T Cell (CAR-T), and Antibody Dependent Cell-mediated Cytotoxicity (ADCC) therapeutics. The company's business model is centered on leveraging its OGAP® platform to discover novel cancer targets and then collaborating with major pharmaceutical companies for further development and commercialization. These partnerships typically involve upfront payments, milestone payments, and royalties on net sales. Oxford BioTherapeutics has established strategic collaborations with companies like Roche, Boehringer Ingelheim, Genmab, Kite Pharma, and ImmunoGen.
One of its lead clinical programs is OBT076, an ADC that entered a U.S. clinical trial in 2021 for patients with advanced or refractory solid tumors such as gastric, bladder, ovarian, and lung cancer. The company operates from its headquarters in Oxford, UK, and has a presence in San Jose, California. In October 2023, it relocated its UK headquarters to The Oxford Science Park to be at the center of the Oxford biotech ecosystem.
Source: Dealroom company dataNews
Open roles
Oxford BioTherapeutics in the Oxford ecosystem
The Oxford BioTherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Oxford Capital
South East Growth Fund & Management
Calculus Capital
Series B and later2 investors entered at this stage
Standard Treasury
Oxford Finance
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oxford BioTherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oxford BioTherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


